41 results about "Neurocognitive Disturbance" patented technology

A user-friendly reliable process is provided to help diagnose (assess) and treat (rehabilitate) impairment or deficiencies in a person (subject or patient) caused by a traumatic brain injury (TBI) or other neurocognitive disorders. The economical, safe, effective process can include: generating and electronically displaying a virtual reality environment (VRE) with moveable images; identifying and letting the TBI person perform a task in the VRE; electronically inputting and recording the performance data with an electronic interactive communications device; electronically evaluating the person's performance and assessing the person's impairment by electronically determining a deficiency in the person's cognitive function (e.g. memory, recall, recognition, attention, spatial awareness) and/or motor function (i.e. motor skills, e.g. balance) as a result of the TBI or other neurocognitive disorder.

A system for detection of noncompliance including substance abuse, driving under influence, and untruthful testimony giving under law enforcement setting, comprising optical sensors for capturing a subject's pupillary responses, blinking eye movements, point-of-gaze, facial expression, and head pose during a compliance test session. The system can also be applied in neurocognitive disorder diagnosis. The subject's affective and cognitive states estimation based on the captured sensory data during a diagnosis test is feedback to the system to drive the course of the compliance or cognitive test, adaptively change the test materials, and influence the subject's affective and cognitive states. The estimated affective and cognitive states in turn provide a more accurate reading of the subject's condition.

The present invention is directed to a set of tableware for use by persons with neuro-cognitive impairment, compromised or under developed motor skills, or any persons with difficulties eating foods and imbibing drinks. As described herein, the tableware set includes at least one container and at least one spoon. The container has a smooth sidewall portion, a vertically slanted basin portion to define an asymmetrical cavity enclosed by the container. A flat base is provided on the underside of the container. A spoon is provided to match the curvature of the container along or more axes. To assist disabled persons with using the spoon, the side edges of the spoon matches the vertical curvature of the sidewall container, and the tip of the spoon matches the horizontal curvature. The handle of the spoon is designed along an arc to match the alignment of a closed hand when holding a spoon.

The invention belongs to the medicine field and provides a borneol-curcumin liposome, a preparation method of the borneol-curcumin liposome and an application of the borneol-curcumin liposome in preparing medicines for preventing human immunodeficiency virus-1(HIV-1) associated neurocognitive disorder. The borneol-curcumin liposome is prepared by, by mass, 270-330 parts of lecithin, 90-110 parts of cholesterol, 0.9-1.1 parts of curcumin and 0.09-0.11 part of borneol. The preparation method includes that the components and 0-11 parts by mass of oxidation protection agents are dissolved by absolute ethyl alcohol, a mixture is subjected to rotary evaporating on a rotary evaporator until ethanol is volatilized to form uniform films, a defined amount of phosphate buffer solution is added, the incubation is performed for three hours, a hydration reaction is undertaken to form an emulsion, then the ultrasound is performed for 10 minutes, and the emulsion passes through a 0.45 micrometer millipore filter to obtain uniform particles so that the borneol-curcumin liposome is obtained. The borneol-curcumin liposome can be prepared to various dosage forms of HIV-associated neurocognitive disorder (HAND) resistant medicines which are peroral, and the pertinence of the borneol-curcumin liposome for treating HAND is high, and the effect is good.

The present invention provides for the production of recombinant human antithrombin (rhAT) for the treatment or prophylaxis of neurocognitive disorders typically associated with major surgical procedures. The recombinant processes of the current invention as well as more efficient methods of treatment, formulation and production have been developed to treat the incidence of neurocognitive problems associated with visuoconstruction, parieto-occipital watershed area injury, hypoperfusion, microemboli or other larger embolic factors and/or CABG procedures secondary to surgery.

A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.

Provided are wearable systems and methods for treatment of a neurocognitive impairment, disease or disorder in a patient in need thereof comprising a visual field occluder useful, for example, in prism adaptation therapy.

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.

The invention is a method for automatic detection of neurocognitive impairment, comprising,

• • generating, in a segmentation and labelling step (11), a labelled segment series (26) from a speech sample (22) using a speech recognition unit (24); and
  • generating from the labelled segment series (26), in an acoustic parameter calculation step (12), acoustic parameters (30) characterizing the speech sample (22).

The method is characterised by

• • determining, in a probability analysis step (14), in a particular temporal division of the speech sample (22), respective probability values (38) corresponding to silent pauses, filled pauses and any types of pauses for respective temporal intervals thereof;
  • calculating, in an additional parameter calculating step (15), a histogram by generating an additional histogram data set (42) from the determined probability values (38) by dividing a probability domain into subdomains and aggregating durations of the temporal intervals corresponding to the probability values falling into the respective subdomains; and
  • generating, in an evaluation step (13), decision information (34) by feeding the acoustic parameters (30) and the additional histogram data set (42) into an evaluation unit (32), the evaluation unit (32) using a machine learning algorithm.

The invention is furthermore data processing system, a computer program product and a computer-readable storage medium for carrying out the method.

The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.

A method and composition for suppressing replication of the HIV-1 virus strains, modulating the production and liberation of inflammatory mediators; and the prevention and treatment of neurocognitive disorders. The method comprises administering to a subject an effective amount of an a macrocyclic diterpenoid, such as 4R cembranoid.

The invention relates to compounds of the following formula: